Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$16.01
At close: May 21 EDT
$16.01
0.000.00%
Pre-Market: 4:32 PM EDT
Comments
Loading...
RxSight Analyst Ratings and Price Targets | NASDAQ:RXST | Benzinga
RxSight Inc has a consensus price target of $39 based on the ratings of 11 analysts. The high is $73 issued by BTIG on July 15, 2024. The low is $16 issued by UBS on April 9, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Piper Sandler, and UBS on May 19, 2025, April 15, 2025, and April 9, 2025, respectively. With an average price target of $19.67 between Wells Fargo, Piper Sandler, and UBS, there's an implied 22.84% upside for RxSight Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Piper Sandler
UBS
JP Morgan
Needham
1calculated from analyst ratings
Analyst Ratings for RxSight
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | 56.15% | Wells Fargo | Larry Biegelsen68% | $17 → $25 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/15/2025 | Buy Now | 12.43% | Piper Sandler | Adam Maeder63% | → $18 | Initiates | → Neutral | Get Alert |
| 04/09/2025 | Buy Now | -0.06% | UBS | Danielle Antalffy60% | $45 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 04/07/2025 | Buy Now | 6.18% | Wells Fargo | Larry Biegelsen68% | $22 → $17 | Maintains | Equal-Weight | Get Alert |
| 04/04/2025 | Buy Now | 6.18% | JP Morgan | Robbie Marcus67% | $40 → $17 | Downgrade | Overweight → Underweight | Get Alert |
| 04/03/2025 | Buy Now | 37.41% | Wells Fargo | Larry Biegelsen68% | $35 → $22 | Maintains | Equal-Weight | Get Alert |
| 04/03/2025 | Buy Now | 168.58% | Needham | David Saxon57% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 124.86% | B of A Securities | Craig Bijou77% | $60 → $36 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 74.89% | Stifel | Thomas Stephan40% | $33 → $28 | Maintains | Hold | Get Alert |
| 02/26/2025 | Buy Now | 149.84% | JP Morgan | Robbie Marcus67% | $62 → $40 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 106.12% | Stifel | Thomas Stephan40% | $35 → $33 | Maintains | Hold | Get Alert |
| 02/26/2025 | Buy Now | 118.61% | Wells Fargo | Larry Biegelsen68% | $40 → $35 | Maintains | Equal-Weight | Get Alert |
| 02/26/2025 | Buy Now | 168.58% | Needham | David Saxon57% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 149.84% | Wells Fargo | Larry Biegelsen68% | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 01/13/2025 | Buy Now | 118.61% | Stifel | Thomas Stephan40% | $40 → $35 | Maintains | Hold | Get Alert |
| 01/13/2025 | Buy Now | 312.24% | Needham | David Saxon57% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 149.84% | Stifel | Thomas Stephan40% | $65 → $40 | Downgrade | Buy → Hold | Get Alert |
| 12/17/2024 | Buy Now | 312.24% | Needham | David Saxon57% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 162.34% | Wells Fargo | Larry Biegelsen68% | $56 → $42 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/06/2024 | Buy Now | 224.8% | UBS | Danielle Antalffy60% | → $52 | Initiates | → Buy | Get Alert |
| 10/29/2024 | Buy Now | 349.72% | Jefferies | Young Li23% | → $72 | Initiates | → Buy | Get Alert |
| 09/13/2024 | Buy Now | 312.24% | Needham | David Saxon57% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/20/2024 | Buy Now | 312.24% | Needham | David Saxon57% | $54 → $66 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 237.29% | Wells Fargo | Larry Biegelsen68% | $68 → $54 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | 306% | Stifel | Thomas Stephan40% | $70 → $65 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 306% | Oppenheimer | Steven Lichtman62% | $72 → $65 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 237.29% | Needham | David Saxon57% | $75 → $54 | Maintains | Buy | Get Alert |
| 07/15/2024 | Buy Now | 355.97% | BTIG | Ryan Zimmerman71% | $72 → $73 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | 337.23% | Stifel | Thomas Stephan40% | $75 → $70 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 324.73% | Wells Fargo | Larry Biegelsen68% | $61 → $68 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | 349.72% | Oppenheimer | Steven Lichtman62% | $61 → $72 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | 368.46% | Needham | David Saxon57% | $64 → $75 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 349.72% | BTIG | Ryan Zimmerman71% | $61 → $72 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 324.73% | Stifel | Thomas Stephan40% | $64 → $68 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 299.75% | Needham | David Saxon57% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 299.75% | Stifel | Thomas Stephan40% | $54 → $64 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 287.26% | JP Morgan | Robbie Marcus67% | $40 → $62 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 281.01% | Oppenheimer | Steven Lichtman62% | $54 → $61 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 299.75% | Needham | David Saxon57% | $53 → $64 | Maintains | Buy | Get Alert |
| 02/12/2024 | Buy Now | 237.29% | Stifel | Thomas Stephan40% | $45 → $54 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 237.29% | Oppenheimer | Steven Lichtman62% | $50 → $54 | Maintains | Outperform | Get Alert |
| 01/16/2024 | Buy Now | 212.3% | Oppenheimer | Steven Lichtman62% | $46 → $50 | Maintains | Outperform | Get Alert |
| 01/08/2024 | Buy Now | 156.09% | Needham | David Saxon57% | $35 → $41 | Maintains | Buy | Get Alert |
| 01/08/2024 | Buy Now | 187.32% | Oppenheimer | Steven Lichtman62% | $38 → $46 | Maintains | Outperform | Get Alert |
| 12/13/2023 | Buy Now | 162.34% | Wells Fargo | Larry Biegelsen68% | → $42 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/12/2023 | Buy Now | 149.84% | Stifel | Thomas Stephan40% | → $40 | Initiates | → Buy | Get Alert |
| 12/04/2023 | Buy Now | 124.86% | Morgan Stanley | Patrick Wood53% | → $36 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | Buy Now | 87.38% | Needham | David Saxon57% | $36 → $30 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 112.37% | Oppenheimer | Steven Lichtman62% | $29 → $34 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 112.37% | Needham | David Saxon57% | → $34 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2023 | Buy Now | 112.37% | Needham | David Saxon57% | $27 → $34 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 81.14% | BTIG | Ryan Zimmerman71% | $25 → $29 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 68.64% | Wells Fargo | Larry Biegelsen68% | $17 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/10/2023 | Buy Now | 68.64% | Needham | David Saxon57% | $22 → $27 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 6.18% | Wells Fargo | Larry Biegelsen68% | $15 → $17 | Maintains | Equal-Weight | Get Alert |
| 04/19/2023 | Buy Now | 37.41% | Needham | David Saxon57% | → $22 | Maintains | Buy | Get Alert |
| 04/13/2023 | Buy Now | 43.66% | Oppenheimer | Steven Lichtman62% | → $23 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 24.92% | JP Morgan | Robbie Marcus67% | $22 → $20 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 37.41% | Needham | David Saxon57% | → $22 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 37.41% | Needham | David Saxon57% | → $22 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | 37.41% | Needham | David Saxon57% | → $22 | Reiterates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | -12.55% | Wells Fargo | Larry Biegelsen68% | $20 → $14 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/09/2022 | Buy Now | 37.41% | Needham | David Saxon57% | $19 → $22 | Maintains | Buy | Get Alert |
FAQ
What is the target price for RxSight (RXST) stock?
The latest price target for RxSight (NASDAQ:RXST) was reported by Wells Fargo on May 19, 2025. The analyst firm set a price target for $25.00 expecting RXST to rise to within 12 months (a possible 56.15% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RxSight (RXST)?
The latest analyst rating for RxSight (NASDAQ:RXST) was provided by Wells Fargo, and RxSight upgraded their overweight rating.
When was the last upgrade for RxSight (RXST)?
The last upgrade for RxSight Inc happened on May 19, 2025 when Wells Fargo raised their price target to $25. Wells Fargo previously had an equal-weight for RxSight Inc.
When was the last downgrade for RxSight (RXST)?
The last downgrade for RxSight Inc happened on April 9, 2025 when UBS changed their price target from $45 to $16 for RxSight Inc.
When is the next analyst rating going to be posted or updated for RxSight (RXST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RxSight, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RxSight was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating RxSight (RXST) correct?
While ratings are subjective and will change, the latest RxSight (RXST) rating was a upgraded with a price target of $17.00 to $25.00. The current price RxSight (RXST) is trading at is $16.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
